Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the diabetic peripheral neuropathy market grown in recent years?
The market size for diabetic peripheral neuropathy has experienced robust growth in the past few years. The market value is projected to rise from $3.51 billion in 2024 to $3.84 billion in 2025, signifying a compound annual growth rate (CAGR) of 9.4%. Aspects such as the growing elderly population, a rise in diabetes cases, increased spending on healthcare, heightened awareness of diabetes-related complications, and expanding healthcare infrastructure have all contributed to the historic period’s growth.
How is the diabetic peripheral neuropathy market size expected to evolve during the forecast period?
The market size for diabetic peripheral neuropathy is forecasted to witness a substantial increase in the coming years, expanding to a value of $5.43 billion by 2029 with a Compound Annual Growth Rate (CAGR) projected at 9.1%. The propelling factors for this anticipated growth involve a rise in sedentary way of living, enhanced initiatives and funding from the government, growing incidence of factors that increase the risk of neuropathy, better diagnostic precision, and an increasing emphasis on early detection and prevention. The forecast period will likely witness advancements like improved diagnostic technologies, progression in treatment alternatives, increased funding in research and innovation, the advent of less invasive procedures, and a greater focus on mutual research and development.
Get your diabetic peripheral neuropathy market report here!
Which key drivers are propelling the diabetic peripheral neuropathy market’s growth?
The growth of the diabetic peripheral neuropathy market is anticipated to be influenced by the rising instances of health complications related to obesity. Obesity is defined as a medical situation where excess body fat accumulates to an extent that it may jeopardize health and elevate the probability of a range of chronic illnesses. The heightened awareness, lifestyle modifications, and an increasing necessity for prevention and treatment are contributing to the growth of obesity-related health problems, thereby leading to higher healthcare needs. Diabetic peripheral neuropathy proves beneficial in controlling obesity by offering vital understanding of nerve damage resulting from conditions associated with obesity. This information aids in formulating targeted strategies to enhance the overall well-being and standard of life of patients. For instance, the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations in charge of worldwide public health, stated in March 2024 that in 2022, 43% of adults over 18 were considered overweight and 16% were reported to be living with obesity. Also, there were 37 million children below the age of 5 who were overweight. Over 390 million children and adolescents between 5 to 19 years old were overweight, comprising of 160 million suffering from obesity. Consequently, the surge in obesity-related health problems fuels the growth of the diabetic peripheral neuropathy market.
What are the market segments in the diabetic peripheral neuropathy industry?
The diabetic peripheral neuropathy market covered in this report is segmented –
1) By Disease: Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy
2) By Treatment: Pain Management Drugs, Gene Therapies
3) By Therapy: Antidepressants, Anticonvulsants
4) By Patient Population: Adult Patients, Geriatric Patients
Subsegments:
1) By Type 2 Diabetic Peripheral Neuropathy: Sensory Neuropathy, Motor Neuropathy, Autonomic Neuropathy
2) By Type 1 Diabetic Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyradiculopathy
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21170&type=smp
Which leading companies are shaping the growth of the diabetic peripheral neuropathy market?
Major companies operating in the diabetic peripheral neuropathy market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc., Eli Lilly and Company, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Sun Pharmaceutical Industries Limited, Lupin Pharmaceuticals Inc., Chemie Grünenthal GmbH, Alkem Laboratories Limited, Acorda Therapeutics Inc., Mitsubishi Tanabe Pharma Corporation, NeuroMetrix Inc., Regenacy Pharmaceuticals Inc., Helixmith Co. Ltd., Aptinyx Inc., WinSanTor Inc., Sonnet BioTherapeutics Holdings Inc., OLYS Pharma Inc.
What emerging trends are influencing the growth of the diabetic peripheral neuropathy market?
Leading firms in the diabetic peripheral neuropathy market are prioritizing technological advancements such as NaV1.8 pain signal inhibitors to offer patients better, opioid-free treatments which enhance pain control and overall life quality. A NaV1.8 pain signal inhibitor is a distinct medication that blocks the NaV1.8 sodium channel, a significant mediator of pain signals in sensory neurons, to offer relief from both acute and neuropathic pain, without dependence on opioids. For example, in April 2024, Vertex Pharmaceuticals Incorporated, a bio-tech firm based in the U.S., proclaimed advancements in its Suzetrigine pain program, including the commencement of a Phase 3 pivotal program for addressing pain related to diabetic peripheral neuropathy (DPN). Suzetrigine, a selective NaV1.8 pain signal inhibitor, has exhibited positive outcomes in previous researches and recently got breakthrough therapy designation for managing DPN pain from the Food and Drug Administration (FDA), a federal agency in the U.S.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21170
Which geographic areas are influencing the growth of the diabetic peripheral neuropathy market?
North America was the largest region in the diabetic peripheral neuropathy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic peripheral neuropathy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Hormone Therapy Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report
Parathyroid Hormone Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report
Global Transdermal Skin Patches Global Market Report 2025
https://thebusinessresearchcompany.com/report/transdermal-skin-patches-market
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
